The PPARγ agonist Pioglitazone was recently associated with lower risk of recurrent stroke in patients with IR, prediabetes and T2D with a history of stroke or transient ischemic attack ([51]) (reviewed in [14,52]). This evidence concerns the gene PPARG and prediabetes syndrome.